{"schema_version":"secwatch.filing_event.v1","accession":"0001906324-23-000030","form_type":"8-K","ticker":"QDEL","cik":"0001906324","company_name":"QuidelOrtho Corp","filed_at":"2023-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.562724+00:00","generated_at":"2026-06-16T01:44:15.237400+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Q1 revenue $846.1M, down 16%; GAAP EPS $0.73, adjusted EPS $1.80","bullets":["Total revenue $846.1M, down 16% YoY; non-respiratory up 5% on supplemental combined basis.","GAAP EPS $0.73 vs $11.31; adjusted EPS $1.80 vs $8.03 on combined basis, down 78%.","Labs business drove non-respiratory growth with double-digit growth; respiratory revenue down 72%.","Adjusted EBITDA $245.3M (29% margin) vs $780.8M (52% margin) in prior year.","Integration on track; guidance to be provided on conference call; expects sustainable high-single-digit growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001906324-23-000030","json":"https://secwatch.observer/filing/0001906324-23-000030.json","markdown":"https://secwatch.observer/filing/0001906324-23-000030.md","text":"https://secwatch.observer/filing/0001906324-23-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1906324/000190632423000030/0001906324-23-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1906324/000190632423000030/qdel-20230503.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T01:44:15.237400+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"041fbb8bc0677d62573184420fd3342b69861398","claim":"QuidelOrtho Corp reported first quarter ended April 2, 2023 results: revenue $846.1 million, EPS $0.73.","evidence_excerpt":"any general incorporation language in such filing. --- EX-99.1 (EX-99.1) --- QuidelOrtho Reports First Quarter 2023 Financial Results Highligh ts • First quarter revenue of $846.1 million decreased by 16% as reported with non-respiratory revenue up 5% on a supplemental combined basis (up 7% in constant currency) and respiratory revenue down 72% on a supplemental","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1906324/000190632423000030/0001906324-23-000030-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended April 2, 2023"},{"label":"Revenue","value":"$846.1 million"},{"label":"EPS","value":"$0.73"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}